PURPOSE: To determine prospectively the prognostic significance of HER-2/neu oncogene amplification in the primary tumors of breast cancer patients. METHODS: HER-2/neu amplification in tumor DNA was determined by the slot-blot technique in 1,056 patients with breast cancer (stage I to III) diagnosed between 1987 and 1990. Parameters such as estrogen receptor (ER) and progesterone receptor (PgR) levels, tumor size, axillary nodal involvement, tumor grade, and time to relapse were prospectively obtained. RESULTS: HER-2/neu oncogene amplification, > or = 2, > or = 3, and > or = 5 copy number, was detected in 21%, 11%, and 7% of patients, respectively. In a test set of 529 patients, Cox multivariate analysis showed HER-2/neu copy number > or = 3 or > or = 5 was associated with shorter disease-free survival (DFS) duration. HER-2/neu copy number > or = 3 correlated significantly with pathologic stage of disease, number of axillary nodes with tumor, histologic type, and absence of ER and PgR. For all patients, after a median follow-up duration of 39 months, Kaplan-Meier univariate analysis indicated that tumor oncogene copy number > or = 3 correlated with shorter DFS in both node-negative and node-positive patients. In Cox multivariate analysis, HER-2/neu copy number > or = 3 was associated with shorter DFS, independent of nodal status, ER level, and tumor size. CONCLUSION: Although the follow-up duration of this study is relatively short, we conclude that HER-2/neu amplification is an independent predictor of shorter DFS in both node-negative and node-positive patients.
PURPOSE: To determine prospectively the prognostic significance of HER-2/neu oncogene amplification in the primary tumors of breast cancerpatients. METHODS:HER-2/neu amplification in tumor DNA was determined by the slot-blot technique in 1,056 patients with breast cancer (stage I to III) diagnosed between 1987 and 1990. Parameters such as estrogen receptor (ER) and progesterone receptor (PgR) levels, tumor size, axillary nodal involvement, tumor grade, and time to relapse were prospectively obtained. RESULTS:HER-2/neu oncogene amplification, > or = 2, > or = 3, and > or = 5 copy number, was detected in 21%, 11%, and 7% of patients, respectively. In a test set of 529 patients, Cox multivariate analysis showed HER-2/neu copy number > or = 3 or > or = 5 was associated with shorter disease-free survival (DFS) duration. HER-2/neu copy number > or = 3 correlated significantly with pathologic stage of disease, number of axillary nodes with tumor, histologic type, and absence of ER and PgR. For all patients, after a median follow-up duration of 39 months, Kaplan-Meier univariate analysis indicated that tumor oncogene copy number > or = 3 correlated with shorter DFS in both node-negative and node-positive patients. In Cox multivariate analysis, HER-2/neu copy number > or = 3 was associated with shorter DFS, independent of nodal status, ER level, and tumor size. CONCLUSION: Although the follow-up duration of this study is relatively short, we conclude that HER-2/neu amplification is an independent predictor of shorter DFS in both node-negative and node-positive patients.
Authors: Raymond Tubbs; James Pettay; Marek Skacel; Richard Powell; Mark Stoler; Patrick Roche; James Hainfeld Journal: Am J Pathol Date: 2002-05 Impact factor: 4.307
Authors: Aimee K Bence; Eric B Anderson; Maqbool A Halepota; Michael A Doukas; Phillip A DeSimone; George A Davis; Deborah A Smith; Kevin M Koch; Andrew G Stead; Steve Mangum; Carolyn J Bowen; Neil L Spector; Showchien Hsieh; Val R Adams Journal: Invest New Drugs Date: 2005-01 Impact factor: 3.850
Authors: Sharareh Siamakpour-Reihani; Haroula J Argiros; Lori J Wilmeth; L Lowell Haas; Tabitha A Peterson; Dennis L Johnson; Charles Brad Shuster; Barbara A Lyons Journal: J Mol Recognit Date: 2009 Jan-Feb Impact factor: 2.137
Authors: M F E Godinho; A M Sieuwerts; M P Look; D Meijer; J A Foekens; L C J Dorssers; T van Agthoven Journal: Br J Cancer Date: 2010-09-21 Impact factor: 7.640
Authors: Y C Cheng; V Valero; M L Davis; M C Green; A M Gonzalez-Angulo; R L Theriault; J L Murray; G N Hortobagyi; N T Ueno Journal: Br J Cancer Date: 2010-09-28 Impact factor: 7.640